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Abstract
Background:	Prebiotics	exert	beneficial	effects	upon	gastrointestinal	 (GI)	environ‐
ment, but this is not always accompanied with a positive effect on GI symptoms. B‐
GOS®	is	a	prebiotic	with	high	selectivity	toward	bifidobacteria	and	a	variety	of	other	
beneficial	 effects	 in	 humans.	Here,	we	 investigated	 its	 effect	 on	GI	 symptoms	 in	
adults who suffer with bloating, abdominal pain, and flatulence.
Methods: In a double‐blind, placebo‐controlled, crossover study, 83 subjects from 
the general population who presented with GI symptoms during screening period 
and	had	a	predicted	probability	of	functional	bowel	disorder	of	more	than	75%	were	
randomized	to	receive	either	a	placebo	or	the	B‐GOS®	treatment	(2.75	g/d).	Subjects	
were screened for the presence of GI symptoms for 1 week, they consumed the 
treatments for 2 weeks, and then went through a 2‐week washout period, before 
switching to the other treatment for the final 2 weeks. GI symptoms, bowel move‐
ments, and stool consistency were assessed in daily and weekly questionnaires. 
Quality	of	life	was	assessed	weekly	and	depression	and	anxiety	at	the	end	of	each	
treatment period.
Results:	B‐GOS®	resulted	in	significantly	(P	<	0.001)	lower	scores	for	bloating,	flatu‐
lence, and abdominal pain both from baseline and placebo at the end of first week. 
The effect was sustained at the end of second week. It had no effect on the number 
of bowel movements, consistency of stools, quality of life, or mood throughout the 
study.
Conclusion:	Results	suggest	that	B‐GOS®	could	possibly	be	used	in	the	management	
of bloating, flatulence, or abdominal pain and warrant further investigation.
K E Y W O R D S
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1  | INTRODUC TION
Prebiotics are substrates that are selectively utilized by host micro‐
organisms conferring a health benefit.1	What	distinguishes	prebiotics	
from other undigested dietary ingredients is their selective fermen‐
tation,	whereby	very	few	groups	or	even	species	of	bacteria	(mainly	
belonging	to	beneficial	groups	of	bifidobacteria	or	lactobacilli)	should	
be able to utilize them. Current confirmed prebiotic status in humans, 
with the most evidence, belongs to inulin, fructooligosaccharides 
(FOS),	 and	 trans‐galactooligosaccharides	 (GOS).1	 Inulin	 and	 FOS	
occur	naturally	in	some	types	of	fruits	and	vegetables	while	GOS	do	
not. They are derivatives of lactose that resemble both structural and 
functional similarities with human breast milk oligosaccharides.2
Bacterial	fermentation	of	carbohydrates	(including	some	prebiot‐
ics)	can	result	in	increased	production	of	gas	and	it	can	also	promote	
symptoms	similar	to	those	of	 irritable	bowel	syndrome	(IBS),	that	 is,	
bloating, flatulence, abdominal pain, and irregular defecation pattern. 
This	may	 especially	 be	 relevant	 in	 individuals	with	 IBS,	 other	 func‐
tional	 bowel	 disorders	 (FBD)	or	 those	 that	 suffer	with	 these	 symp‐
toms. These individuals are known to have altered GI environment 
such as motility,3 increased fermentation,4 visceral hypersensitivity,5 
abnormal gas transit,6 and dysbiosis of the GI microbiota.7	Exclusion	
of fermentable substrates from the diet has attracted some interest 
lately,	as	a	potential	treatment	of	IBS	symptoms.	Studies	show	that	the	
removal of fermentable oligosaccharides, disaccharides, monosaccha‐
rides,	and	polyols	 (FODMAPS)	can	be	effective	 in	 repressing	symp‐
toms	in	IBS	sufferers.8	However,	this	strategy	may	be	criticized	for	its	
negative effects on GI environment, in terms of metabolism9,10 and al‐
tered composition of GI microbiota.11‒13	Almost	without	exception,	all	
FODMAPS	contain	fructose	and	the	symptom	induction	after	inges‐
tion of these substrates is well documented in both uncontrolled14,15 
and controlled16,17	trials.	Similarly,	prebiotics	such	as	 inulin	and	FOS	
also contain fructose and, regardless of their positive effect upon GI 
environment, have been shown to either result in side effects such as 
increased bloating, flatulence, or abdominal pain or to have no impact 
on	these	GI	symptoms	in	healthy	adults	and	those	with	IBS.18‒22
B‐GOS	(Bimuno®)	is	composed	of	galactose	chains	and	it	has	been	
shown to have a potent prebiotic effect with high selectivity toward 
bifidobacteria and a variety of other beneficial effects in humans.23‒27 
In	 IBS	 sufferers,	 it	 reduced	 bloating	 and	 abdominal	 pain	 without	
changes to their diets,28 and in healthy adults, it was shown not to 
result in GI symptoms.29,30 The aim of the current study was to under‐
stand	 the	effect	of	B‐GOS®	administration	 to	adults	 selected	 from	
the general population who often suffer with bloating, abdominal pain, 
or	 flatulence	but	who	are	not	 formally	diagnosed	with	 IBS	or	other	
forms	of	FBD,	in	a	double‐blind,	placebo‐controlled,	cross‐over	study.
2  | METHODS
2.1 | Study population
The	participants	were	 selected	 from	 the	University	of	Reading	data‐
base that holds some medical, demographic, lifestyle, and medication 
information about volunteers in the general population who are will‐
ing to participate in various trials undertaken by the university. One 
hundred	and	twenty	subjects	aged	18‐65	years	suffering	often	(at	least	
three	times	per	month)	from	GI	symptoms	were	invited	into	the	study.	
They	were	selected	on	the	following	exclusion	criteria:	history/diagno‐
sis of GI disease, surgical resection of the bowel, history of malignancy 
within previous five years, use of antibiotics in the 4 weeks before the 
study, consumption of pre/probiotic preparations on the regular basis 
(three	or	more	times	per	week)	 in	the	2	weeks	before	the	study,	for‐
mer participation in another similar study within the previous month, 
severe allergy or history of allergic reaction, drug or alcohol use, preg‐
nant/lactating,	and	regular	use	of	any	medication	with	 the	exception	
of	hormonal	 replacement	 therapy	or	 contraception.	Subjects	 (n	=	91)	
who	presented	with	moderate	to	severe	GI	symptoms	(bloating,	flatu‐
lence,	abdominal	pain)	assessed	using	a	4‐point	Likert	scale	(0	=	none,	
1	=	present	 but	 tolerated,	 2	=	present	 interfering	 but	 not	 preventing	
activities,	3	=	preventing	daily	activities)	for	a	minimum	of	2	days	dur‐
ing 1 week of screening period and had a Bowel Disease Questionnaire 
(BDQ)31	 predicted	 the	 probability	 of	 FBD	 of	 more	 than	 75%	 (score	
≥	629)	were	randomized.	Of	these,	eight	subjects	did	not	complete	the	
trial	(one	used	antibiotics,	one	was	hospitalized	due	to	a	broken	leg,	one	
relocated,	five	failed	to	make	contact	with	 investigators).	The	sample	
size	required	to	give	a	power	of	95%	for	detecting	a	treatment	differ‐
ence	at	a	two‐sided	0.05	significance	level	for	the	intestinal	symptoms	
(bloating,	 abdominal	 pain,	 flatulence),	 if	 the	 true	 difference	 between	
treatments	is	0.4	units,	was	calculated	to	be	77	subjects.
2.2 | Study design
Eligible subjects were enrolled into a prospective, single‐center, 
randomized, double‐blind, placebo‐controlled, crossover study. 
The	study	 lasted	7	weeks	and	consisted	of	 four	periods:	a	screen‐
ing period for the presence of symptoms and BDQ score of 1 week, 
subjects consumed treatments for 2 weeks, followed by a 2‐week 
washout	period	(without	consuming	any	treatments),	before	switch‐
ing	onto	 the	other	 treatment	 for	 the	 final	2	weeks	 (Figure	1).	The	
Key Points
• Prebiotics are beneficial to GI environment but those 
that contain fructose sometimes result in discomfort. 
B‐GOS	 is	 a	 galactose‐based	 prebiotic,	 highly	 selective	
toward beneficial bifidobacteria and its effect on GI 
symptoms was tested in symptomatic but not formally 
diagnosed adults with functional bowel disorder.
•	 More	than	90%	of	subjects	experienced	significant	relief	
of bloating, abdominal pain, and flatulence following 2 
weeks	supplementation	with	B‐GOS.
•	 B‐GOS	might	be	a	potential	candidate	for	use	in	dietary	
management of bloating, flatulence, or abdominal pain.
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study	included	seven	visits:	a	screening	(visit	1)	prior	to	enrolment,	
randomization	and	baseline	for	treatment	1	(visit	2),	after	1	week	of	
treatment	 (visits	3	and	6),	at	the	end	of	2	weeks	treatment	 (visit	4	
and	7),	baseline	for	treatment	2	(visit	5).
Subjects	were	stratified	by	gender	using	a	block	size	of	10	and	
randomly	 assigned,	 using	 a	 random	 number	 generator	 (https://
www.random.org),	in	a	1:1	ratio	into	two	groups.	One	group	(n	=	45)	
started	with	 a	 prebiotic	 B‐GOS	 (Bimuno®)	 and	 the	 other	 (n	=	46)	
with	a	placebo	 (Maltodextrin).	Both	were	supplied	 in	powder‐con‐
taining	sachets	(2.75	g)	and	provided	by	Clasado	Ltd,	UK.	Subjects	
were asked to reconstitute contents of the sachets immediately be‐
fore	consumption	by	mixing	the	powder	with	water	and	to	consume	
the	product	every	day	at	approximately	the	same	time.	They	were	
also instructed not to alter their diet or fluid intake during the study. 
The	daily	dose	of	 the	active	 ingredient	 (GOS)	provided	 in	a	2.75	g	
sachet	was	1.37	g.
The study was conducted according to the ethical principles 
stated	in	the	Declaration	of	Helsinki.	Ethical	approval	for	the	proto‐
col	was	obtained	from	the	University	of	Reading	(UK)	Review	Board,	
and all participants gave written informed consent to participate in 
the trial and prior to any assessments.
2.3 | Outcomes
The	 effect	 on	 GI	 symptoms	 (bloating,	 abdominal	 pain,	 flatulence,	
urgency)	was	assessed	daily	using	a	self‐report	questionnaire	with	
a	4‐point	Likert	scale	 (0	=	none,	1	=	present	but	tolerated,	2	=	pre‐
sent	 interfering	 but	 not	 preventing	 activities,	 3	=	preventing	 daily	
activities).	 It	was	also	assessed	at	 the	end	of	each	week	using	 the	
Subjective	 Global	 Assessment	 (SGA)	 of	 relief	 (1	=	completely	 re‐
lieved,	 2	=	considerably	 relieved,	 3	=	somewhat	 relieved,	 4	=	un‐
changed,	5	=	worse).	The	number	of	bowel	movements	per	day	and	
stool consistency was also assessed daily in a self‐report question‐
naire. Bowel movement frequency was recorded as numbers per 
day,	 and	consistency	was	 scored	on	a	7‐point	 scale	and	evaluated	
using	the	Bristol	Stool	Scale.
Quality	of	life	(QOL)	was	assessed	at	the	end	of	each	week	using	
the	IBS‐36	questionnaire,	with	scores	symptoms	on	a	7‐point	Likert	
scale	 (0	=	never	 and	 6	=	always).	 Anxiety	 and	 depression	were	 as‐
sessed	 at	 the	 end	 of	 each	 treatment	 period	 using	 the	 Hospital	
Anxiety	 and	Depression	 (HAD)	 scale,	which	 detects	 the	 states	 of	
anxiety	and	depression	with	score	ranges	for	“non’case,”	“doubtful”	
case,	and	“definite”	case.
Participants also recorded daily in their diary about the consump‐
tion of the study products, medications started during the study as 
well as any adverse events.
2.4 | Statistics
Baseline	demographic	data	(end	of	week	1	and	end	of	week	5)	were	
compared	between	groups	using	Student’s	t test, χ2	test,	or	Fisher’s	
exact	test,	when	appropriate.
All	data	were	analyzed	by	an	analysis	of	variance	(ANOVA)	model	
of repeated measurements taking into an account the crossover de‐
sign. In the ANOVA model, treatment period, treatment, and sub‐
ject	were	introduced	as	fixed	effects	and	measurements	as	random	
effect. The efficacy for GI symptom scores was the average of the 
daily	repeated	measurements	recorded	over	a	week	(or	a	number	of	
F I G U R E  1  Study	flow	design
Visit1            Visit2 Visit3 Visit4               Visit5               Visit6                              Visit7
   R a n d o m I z a t I o n        C r o s s I n g   O v e r
                 Screening period Treatment period I Wash out period Treatment period II
             All volunteers (n = 120) 
2.75g/d B-GOS 
                 Containing 1.37g/d GOS 
2.75g/d placebo  
(Maltodextrin)  
. 2.75g/d B-GOS 
                Containing 1.37g/d GOS 
2.75g/d placebo 
(Maltodextrin)
1 wk                              2 wk
Weekly visits 
                       2 wk
                             2 wk 
Weekly visits 
(n = 45) 
                 (n = 46) 
(n = 42) 
(n = 41) 
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recorded	days	in	a	week)	and	calculated	in	the	‘per	protocol’	popu‐
lation.	Significant	differences	between	treatments	were	established	
by	 using	Dunnet’s	 least	 significant	 difference	 test	 (two‐tailed).	 All	
statistical tests were performed using spss	 version	17.0	 (SPSS	 Inc,	
Chicago,	IL,	USA).
3  | RESULTS
3.1 | Baseline characteristics
The	average	age	of	subjects	 in	the	study	was	35.5	±	8.4	years	and	
the	average	BDQ	score	was	635.4	±	7.4.	A	slightly	higher	population	
of	women	 (57%)	 than	men	 (43%)	were	 included	overall,	 but	 there	
were no differences between their measurements. These character‐
istics at baseline did not differ significantly between groups.
3.2 | Compliance with product consumption
The self‐reported levels of product consumption did not differ 
significantly	 between	 the	 groups	 (97.2	±	5.9	 for	 the	 B‐GOS®	 and	
96.3	±	6.7	for	the	placebo	treatment).
3.3 | Analysis of GI symptoms
Weekly	 interval	 averages,	 calculated	 from	 a	 self‐report	 question‐
naire of daily GI symptoms, did not differ significantly at baseline 
(Figure	 2).	 However,	 after	 1	week	 of	 supplementation,	 B‐GOS®	
resulted	 in	 significantly	 (P	<	0.001)	 lower	 scores	 for	 bloating,	 flat‐
ulence, and abdominal pain both from baseline and placebo. This 
effect	 was	 also	 significant	 (P	<	0.001)	 after	 2	weeks	 compared	 to	
baseline	and	placebo	but	not	compared	to	week	1	of	B‐GOS®	treat‐
ment	(Figure	2).	There	was	no	effect	of	the	treatments	on	urgency	
after	week	 1,	 but	 a	 significantly	 (P	<	0.001)	 lower	 score	 in	 the	 B‐
GOS®	group	was	achieved	after	week	2	compared	to	baseline	and	
placebo	(Figure	2).
Additionally,	 Figure	 3	 shows	 the	 proportion	 of	 subjects	 in	 the	
B‐GOS®	group	who	experienced	a	significant	relief	to	or	below	the	
“present	but	tolerated”	level	of	GI	symptoms	(calculated	as	a	weekly	
average	of	recorded	daily	responses	from	a	self‐report	questionnaire)	
during the trial period. All these values were significantly different 
from	the	placebo	group,	where	only	flatulence	was	reduced	in	17%	
of	subjects	(4%	below	“present	but	tolerated”)	after	the	first	week.	
However,	at	the	end	of	week	2,	only	2%	experienced	relief	of	flat‐
ulence	to	“present	but	tolerated”	levels	(data	not	shown).	Bloating,	
flatulence,	and	abdominal	pain	in	subjects	receiving	B‐GOS®	were	
relieved	in	a	 large	majority	 (51%	bloating,	80%	flatulence,	76%	ab‐
dominal	 pain)	 after	 week	 1	 and	 in	 almost	 all	 (98%	 bloating,	 96%	
flatulence,	92%	abdominal	pain)	by	the	end	of	week	2	(Figure	3).	A	
quarter of subjects had bloating and abdominal pain relieved below 
the	“present	but	tolerated”	level	after	week	1	and	bloating	was	fur‐
ther	 improved	 in	72%	of	subjects	at	 the	end	of	week	2	 (Figure	3).	
Flatulence	was	 relieved	below	 the	 “present	 but	 tolerated”	 level	 in	
72%	of	subjects	after	first	week	and	in	84%	after	week	2	(Figure	3).	
Urgency	was	reduced	to	or	below	the	“present	but	tolerated”	level	in	
7%	of	subjects	after	week	1	and	in	87%	at	the	end	of	week	2,	how‐
ever,	no	subjects	experienced	complete	relief	in	urgency	at	the	end	
of	week	1,	but	57%	did	at	the	end	of	week	2	(Figure	3).
3.4 | Stool characteristics, QOL, HAD, and SGA
Stool	characteristics,	QOL,	HAD,	and	SGA	scores	did	not	differ	sig‐
nificantly at baseline. Both treatments appeared to have no effect 
on the number of bowel movements, consistency of stools, QOL, or 
HAD	(Table	1).	However,	SGA	was	significantly	(P	<	0.05)	lower	after	
both	week	1	and	2	in	the	B‐GOS®	group	compared	to	baseline	and	
placebo,	but	it	did	not	differ	between	the	weeks	(Table	1).
4  | DISCUSSION
The	effect	of	a	prebiotic	B‐GOS®	against	a	placebo	on	GI	symp‐
toms in undiagnosed adults, selected from a general population on 
the	presence	of	GI	symptoms	and	with	a	probability	of	FBD,	was	
investigated in this study. The results showed an overall significant 
F I G U R E  2  Mean	daily	scores	±	SD	
(n	=	83)	for	bloating,	flatulence,	
abdominal pain, and urgency in subjects 
with	gastrointestinal	(GI)	symptoms	
during the trial period with a prebiotic 
galactooligosaccharide	(B‐GOS®)	and	
a placebo. The mean scores in the B‐
GOS®	group	were	significantly	(P	<	0.05)	
different from the placebo group and 
the baseline at week 2 for all symptoms 
shown	and	for	all	except	urgency	at	week	
1 too. Assessed with a 4‐point Likert 
scale	(0	=	none;	1	=	present	but	tolerated;	
2	=	present	interfering	but	nit	preventing	
activities;	3	=	preventing	daily	activities)
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improvement in bloating, flatulence, and abdominal pain to or 
below	the	“present	but	tolerated”	 level	after	1	week	of	B‐GOS®	
administration. This improvement was not accompanied with an 
effect on stool consistency or frequency, but it was sustained dur‐
ing the second week of the study, when the urgency scores were 
improved too.
B‐GOS®	is	a	prebiotic	metabolized	or	fermented	by	GI	bacte‐
ria,	making	 it	 a	FODMAP	by	 the	current	definition.	The	 removal	
of	 FODMAPS	 from	 the	 diet	 has	 received	 considerable	 attention	
recently, because of a growing number of studies confirming its 
therapeutic	 effect	 in	 managing	 IBS	 symptoms.8 Their mecha‐
nism of symptom induction is related to an increase in intestinal 
water content, alteration in motility, and colonic gas production. 
However,	this	type	of	diet	reduces	daily	intake	of	fermentable	car‐
bohydrates	by	more	 than	50%11 and not surprisingly results in a 
significant reduction in bacterial saccharolytic fermentation, un‐
doubtedly shifting the GI environment to a less favourable state 
for	 health.	 Strategies	 that	 could	 be	 added	 to	 low	FODMAP	diet	
or offer an alternative dietary approach, to individuals that suf‐
fer	with	GI	symptoms,	are	therefore	of	interest.	Since	administra‐
tion	 of	 B‐GOS®	 in	 the	 current	 study	 did	 not	 result	 in	 symptom	
induction	but	an	 improvement	 in	more	 than	90%	of	 subjects	 for	
bloating, flatulence, and abdominal pain at the end of study pe‐
riod, it appears that its mechanism of action may not be similar to 
FODMAPS.
The	present	 study	did	not	enroll	 diagnosed	 IBS	or	FBD	pop‐
ulations, known to have a more sensitive GI environment than 
healthy subjects.3‒7	 However,	 persons	 were	 enrolled	 from	 the	
general	population	with	a	predicted	FBD	probability	of	more	than	
75%	(score	≥	629)	based	on	a	previously	validated	BDQ	question‐
naire.31	The	BDQ	was	extensively	tested	and	found	to	be	reliable	
(,	 0.81)	with	 adequate	 content	 and	 predictive	 and	 construct	 va‐
lidity.32	 More	 importantly,	 subjects	 were	 enrolled	 experiencing	
bloating, flatulence, or abdominal pain at the start of the study. 
Reports	 suggest	 that	between	20%	and	45%	of	general	western	
population	experiences	these	symptoms,	and	in	more	than	75%	of	
F I G U R E  3  A	proportion	(%	total)	
of	subjects	with	gastrointestinal	(GI)	
symptom	relief	to	(1)	and	below	(<1)	
“present	but	tolerated”	level	during	
the trial period with a prebiotic 
galactooligosaccharide	(B‐GOS®).	All	
values	were	significantly	(P	<	0.05)	
different from the placebo group where 
only	flatulence	was	reduced	to	“present	
but	tolerated”	level	in	17%	and	2%	of	
subjects at the end of week 1 and 2, 
respectively	(data	not	shown).	Assessed	
with	a	4‐point	Likert	scale	(0	=	none;	
1	=	present	but	tolerated;	2	=	present	
interfering but nit preventing activities; 
3	=	preventing	daily	activities)
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TA B L E  1  Comparison	of	Self	Global	Assessment	(SGA),	Quality	of	Life	(QOL),	Hospital	Anxiety	and	Depression	(HAD),	and	stool	
characteristics	during	the	trial	period	with	a	prebiotic	galactooligosaccharide	(B‐GOS®)	and	a	placebo
B‐GOS® (n = 83) Placebo (n = 83)
Baseline Week 1 Week 2 Baseline Week 1 Week 2
SGAa 4.3	±	0.7 2.7	±	0.7e 2.1	±	0.5e 4.1	±	0.5 3.9	±	0.6 4.2	±	0.6
QoLb 73.8	±	40.9 77.4	±	38.5 79.1	±	40.2 72.6	±	41.4 73.8	±	38.5 75.2	±	36.6
HADc 5.6	±	2.8 5.4	±	2.3 5.7	±	2.2 6.0	±	2.6 5.7	±	2.9 5.8	±	2.6
Stool	frequency	per	wkd 11.9	±	4.7 11.5	±	4.0 11.6	±	4.1 10.6	±	5.0 9.8	±	3.9 10.7	±	3.4
Stool	consistencyd 3.7	±	1.1 3.5	±	1.0 3.7	±	1.1 3.4	±	1.1 3.5	±	1.1 3.3	±	1.1
All	data	are	expressed	as	mean	±	SD.	No	significant	differences	were	found	between	treatments	at	baseline	in	shown	variables.
aAssessed	with	a	5‐point	Likert	scale	(1	=	completely	relieved,	2	=	considerably	relieved,	3	=	somewhat	relieved,	4	=	unchanged,	5	=	worse).	
bAssessed	using	IBS‐36	questionnaire.	
cAssessed	using	the	Hospital	Anxiety	and	Depression	(HAD)	scale.	
dAssessed using the Bristol stool scale. 
eSignificantly	different	from	baseline	and	placebo.	
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cases symptoms are moderate to severe.33,34	Furthermore,	studies	
also	suggest	that	almost	half	of	FBD	patients	are	not	formally	diag‐
nosed, so the majority are self‐treated.35 As such, since bloating, 
flatulence, or abdominal pain were present in the subjects enrolled 
in the current study, regardless of the validity of the BDQ ques‐
tionnaire,	and	thus,	the	possibility	of	FBD	diagnosis	in	these	indi‐
viduals which was not the aim of the study, a significant reduction 
in symptoms is of relevance.
The	current	study	used	a	relatively	 low	daily	dose	of	2.75	g	B‐
GOS	 (1.37	g	 per	 day	 of	 an	 active	 ingredient)	 compared	 to	 much	
higher doses of 10‐20 g per day of other previously tested prebi‐
otics	 (eg,	 inulin	 and	 FOS)	 that	 resulted	 in	 a	 FODMAP	 effect.18‒20 
Higher	doses	of	prebiotics	are	likely	to	lose	their	selectivity	on	the	
microbiota and thus possibly increase motility and small intestinal 
water	content.	However,	 these	prebiotics	have	been	 tested	 in	 IBS	
population	 at	much	 lower	 dose	 of	 2‐5	g	 per	 day,	when	worsening	
of the symptoms was not observed but neither was an improve‐
ment.21,22	At	the	same	dose	of	1.37	g	per	day	of	an	active	ingredient,	
B‐GOS®	was	previously	shown	to	reduce	bloating,	flatulence,	and	
abdominal	pain,	with	no	effect	on	stool	consistency,	in	IBS	popula‐
tions after 4 weeks of supplementation.28 The treatment period was 
shorter	here	 than	 in	 the	 IBS	study,	however	selective	 increases	 in	
bifidobacteria,	 and	 at	much	 higher	 rate	 than	 other	 types	 of	GOS,	
after	1	week	of	supplementation	with	B‐GOS	in	healthy	adults	was	
previously shown.23 A selective increase in bifidobacteria was also 
confirmed	in	other	populations	such	as	IBS	patients,28 elderly,24 and 
overweight.25 Bifidobacteria lack a number of key enzymes involved 
in	 the	Emden‐Meyerhof‐Parnas	pathway,	 so	 instead	 they	metabo‐
lize	 carbohydrates	 through	 a	metabolic	 pathway	 named	 the	 “bifid	
shunt”	which	does	not	involve	generation	of	gas.36 Thus, substrates 
such	as	B‐GOS®	that	are	highly	selective	toward	bifidobacteria,	are	
unlikely to contribute to increase in gas production when used at an 
appropriate dose. Indeed, gas homeostasis occurring within a week 
of	administration	with	B‐GOS®,	as	a	result	of	metabolic	and	com‐
positional microbiota changes was previously shown in adults.29,30 
Thus, it is not unreasonable to suggest that its positive effect in re‐
ducing the GI symptoms in the current study, can be contributed to 
its positive effect on microbiota and specifically bifidobacteria.
Alterations in the composition of microbiota and specifically 
reduced	numbers	of	bifidobacteria	have	been	reported	in	FBD.37 
Some	key	factors	involved	in	the	pathogenesis	or	symptom	gener‐
ation	in	FBD	population	are	known	to	be	influenced	by	microbiota.	
For	 example,	 visceral	 hypersensitivity	 or	 reduced	 intestinal	mo‐
tility are associated with low counts of bifidobacteria and higher 
levels of other, less beneficial, members of the GI microbiota.38 
Positive effects of an appropriate microbiota composition has 
also	been	shown	in	other	aspects	relevant	to	FBD,	such	as	reduc‐
tion in stress, improved intestinal permeability, and the effect on 
immune activation.37 It is not surprising, therefore, that some of 
most successful probiotics used in the management of bloating, 
flatulence, and abdominal pain belong to species of bifidobacte‐
ria.39	 However,	 the	 efficacy	 of	 probiotics	 is	 not	 only	 strain	 but	
also individual dependent and therefore, multistrain preparations 
may have better effect in reducing symptoms than single species. 
Prebiotics have an advantage over probiotics in that they support 
the	growth	of	host’s	own,	well‐established,	beneficial	microbiota—
usually	at	the	genus	level.	However,	 in	some	cases	as	mentioned	
above,	they	contribute	to	exacerbation	of	symptoms	due	to	their	
chemistry or fermentative nature, particularly at high doses.
In conclusion, the present study showed a significant reduc‐
tion in bloating, flatulence, and abdominal pain in an undiagnosed, 
adult, population that often suffers with these symptoms. The ef‐
fect	was	evident	after	a	week	of	supplementation	with	B‐GOS®	
and	 sustained	 during	 the	 second	week	 of	 the	 study	when	 92%,	
96%,	and	98%	of	subjects	experienced	relief	to	or	below	the	“pres‐
ent	but	tolerated”	level	for	abdominal	pain,	flatulence,	and	bloat‐
ing, respectively. Although it might be more appropriate to assess 
the	effect	of	B‐GOS®	on	 these	 symptoms	 in	a	diagnosed	popu‐
lation, or for a longer period, it is possible to suggest its poten‐
tial in the management of these symptoms and to warrant further 
investigations.
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